Indago Medical bundle
See your bundle Join the waitlist →
Bundle 03 · MedicalAudience · clinical reviewers, pharmacovigilance, trial offices

The trial result that wasn't published.

Screen thousands of abstracts in seconds — no patient record leaves the institution.

Early access · PRISMA-ready in one afternoon
See the demosJoin the waitlist →
CLINICAL FLOORThe trial you actually ran.
Weeks → an afternoonA systematic review that took 6 weeks of dedup & screening finishes today.
Every result, every trialPubMed + CT.gov + Cochrane + ICTRP + EU CTR + medRxiv · cited at protocol-line level · anti-fab gated.
Catch missing outcomesOutcome-switching, COI non-disclosure and underpowered-sample scans run automatically.
HIPAA-safe by designPatient records never leave the institution. Air-gapped option for hospital networks. Try yourself for free →

The result that didn't make it into the paper.

Systematic reviewers spend weeks deduplicating, screening, and chasing missing outcomes. Indago indexes PubMed, ClinicalTrials.gov, Cochrane, ICTRP, the EU Clinical Trials Register, medRxiv, openFDA and Retraction Watch locally — and runs the missing-results, COI-non-disclosure, p-hacking and underpowered-sample scans alongside the search. Every cited chunk_id resolves; emit is rejected otherwise.

I · Three questions a working medical team asks

From review screening to DDI to missing results.

Demo 1 · Systematic review · GLP-1 + cardiovascular outcomes2.1 ms · local
RCT · GLP-1 receptor agonist · MACE primary endpoint · 2018–2025 · n ≥ 500
01
Multinational RCT, n=8,300 · MACE HR 0.74 (95% CI 0.62–0.88). Primary endpoint met. PubMed · PMID 35621408 · NEJM · 2022 · Tab. 2
0.96
02
Phase 3 vs. SGLT2; composite endpoint widened post-hoc — flagged. ClinicalTrials.gov · NCT0… · 2023 · arm B
0.88
03
Internal protocol — your team's screening sheet for the same inclusion criteria. file://review/glp1-mace/screening.xlsx · 2024 · local
0.81
PubMed + CT.gov + internal reviewsigned export → PRISMA-ready CSV
Demo 2 · Retraction & outcome-switching auditscan · weekly
included-in-review studies · retraction-check + outcome-switching · since 2022
01
Retraction match — PMID cross-referenced against Retraction Watch; cited paper retracted 2024-08. Retraction Watch · DOI 10.1186/… · retraction notice 2024-08-12
0.97
02
Outcome-switching: protocol → publication primary-endpoint changed; secondary became primary. CT.gov · NCT0… · scan · anomaly.research.outcome-switching
0.91
03
Local note: investigator team flagged on a separate review's COI table — cross-review consistency. file://reviews/2024-cardiac/COI.csv · local · scan · anomaly.medical.coi-non-disclosure
0.83
Retraction Watch + CT.gov + your review libraryfindings emit anti-fab gated
Demo 3 · Missing-result audit on the trial registryscan · weekly
CT.gov entries with primary completion ≥ 24 mo ago and no posted result · sponsor: industry
01
Phase 3 oncology — primary completion 2022-08, no result, no publication, sponsor still listed. CT.gov · NCT0… · result missing 39 mo
0.92
02
Cardiology arm, secondary endpoints reclassified after completion — flagged for outcome-switching. scan · anomaly.research.outcome-switching · 2026-Q1
0.87
03
Site investigator listed on three unrelated trials with undisclosed industry consulting. scan · medical.coi-non-disclosure · 2026-Q1
0.79
missing-result + outcome-switching + COIdelivered as weekly oversight digest

No patient identifier ever leaves the institution. Public-source caches stay on the workstation.

II · What's included

Trial registry, label, review library.

The Medical bundle activates clinical and pharmacology sources plus the medical scan family. Layer it with Life sciences if your work crosses into genomics; with Legal for regulatory submissions.

  • PubMed · ClinicalTrials.gov · Cochrane · ICTRP · EU CTR · medRxivauthenticated bulk + delta · ~1.4 M new abstracts/yr
  • openFDA · Retraction Watchlabels + adverse events · retraction notices for cross-check at emit
  • Native renderers
    prisma with study-flow payload · claims-ledger aggregator profile pico · validation-binder for reg-grade.29-template surface
  • Anti-fabrication rail
    indago_finding_emit rejects unresolvable evidence_chunk_id — no fabricated PMIDs.guard at emit
  • Missing-result · outcome-switching · COI · retraction-checkscan · anomaly.med.unregistered-trial · anomaly.research.outcome-switching · anomaly.med.missing-conflict-disclosure · quality.literature.retraction-check
  • Chain-of-custody
    Every PRISMA + claims-ledger render appended to the journal. indago_journal(op=verify). See audit chain.21 CFR / GxP — validation-binder framework labels
Sources of record PubMedClinicalTrials.govCochraneICTRPEU CTRmedRxivopenFDARetraction Watch
II.5 · Sample workflows

Real workflows. Real numbers.

Three workflows shaped for this bundle. Where the box reads Verified, the numbers come from a real run logged in this codebase. Where it reads Pending validation, the workflow shape is implemented and we are still gathering the headline numbers before we publish them.

Workflow 01 Pending validation

Systematic review · GLP-1 · MACE

Cochrane-style reviewers
  1. InputInclusion criteria: RCT · GLP-1 receptor agonist · MACE primary endpoint · n ≥ 500 · 2018–2025.
  2. MethodCross-source ranking over PubMed + ClinicalTrials.gov + Cochrane, with anomaly.research.outcome-switching and anomaly.med.missing-conflict-disclosure scans running in parallel.
  3. OutputPRISMA flow with Identified → Screened → Included counts plus a CSV of flagged trials.
Weeks → afternoon Workflow path runs against public sources today — pending a reviewer-team end-to-end test before we publish numbers.
Workflow 02 Pending validation

Pharmacovigilance · missing-result audit

PV office
  1. InputSponsor portfolio, primary-completion cut-off 24 months prior, industry-sponsored only.
  2. Methodanomaly.med.unregistered-trial + anomaly.research.outcome-switching + anomaly.med.missing-conflict-disclosure scans over the registry slice.
  3. OutputWeekly oversight digest with per-trial overdue intervals and outcome-switching deltas.
Overdue trials Engine runs; pending live PV office run against a real sponsor portfolio.
Workflow 03 Pending validation

Point-of-care DDI · apixaban + clarithromycin

Clinical pharmacists
  1. InputTwo medication identifiers and patient age band.
  2. MethodLocal cross-reference of openFDA labels and the trust's internal anticoagulation protocol; flagging where label guidance and protocol diverge.
  3. OutputRanked DDI card with mechanism, AUC delta, FDA label citation and the internal protocol section.
Sub-second lookup Lookup latency demonstrable on the cached data — pending hospital EHR-plug-in deployment trial.

Verified workflows are reproducible against the index hash listed in each run. Pending workflows are a written commitment, not a customer quote — we publish numbers only when we have measured them.

Medical bundle · from €499/ seat / month · institutional rollouts · all clinical sources · scan family included
III · Also useful for clinical work
LIFE · Life sciencesGenomics & pathwayUniProt · KEGG · Ensembl — gene-name collisions and pathway inconsistencies. LAW · LegalRegulatory submissionsEUR-Lex, FDA guidance, EMA/EDPB — cited under the directive you actually filed under. RES · ResearchBroad scholarly literaturearXiv quant-bio · OpenAlex · Semantic Scholar — non-clinical scientific context.
Indago is an information-retrieval tool, not a medical device or clinical decision-support system. Outputs are for research and informational purposes only and are not medical advice. "HIPAA-safe by design" refers to local, on-premise data handling; HIPAA compliance remains the responsibility of the operating organisation.